Intratumoral CD8+ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Chen, Zonglin ^a   Chen, Xianyu ^a   Zhou, Enxiang ^a   Chen, Ganlong ^a   Qian, Ke ^a   Wu, Xia ^a   Miao, Xiongying ^a   Tang, Zhonghua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGE; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CYTOTOXIC LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE; BREAST TUMOR; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LYMPHATIC METASTASIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84899685321     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095475     Document Type: Article

References (38)

1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, et al. (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol 20(8): 1319-1329.
2. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, et al. (2012) A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin Kappa C as a compatible prognostic marker in human solid tumor. Clin Cancer Res 18(9): 2695-2703.
3. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, et al. (2010) Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptorpositive and negative cancers. J Clin Oncol 28(28): 4316-4323.
4. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, et al. (2009) T-cell metagene predicts a favorable prognosis in estrogen-negative and HER-2 positive breast cancer. Breast Cancer Res 11(2): R15.
5. Lee SC, Srivastava RM, López-Albaitero A, Ferrone S, Ferris RL (2011) Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 50(2-3): 248-254.
6. Chen Z, Gerhold-Ay A, Gebhard S, Boehm D, Solbach C, et al. (2012) Immunoglobulin Kappa C predicts overall survival in node-negative breast cancer. Plos One 7(9): e44741.
7. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, et al. (2011) The prognostic significance of B lymphocytes in invasive cancer of the breast. Breast Cancer Res Treat 132(2): 545-553.
8. Campbel MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, et al. (2010) Proliferating macrophages associated with high grade, homone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 128(3): 703-711.
9. Tadmor T, Zhang Y, Cho HM, Podack ER, Rosenblatt JD (2011) The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol immunother 60(5): 609-619.
10. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, et al. (2011) An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 127(1): 99-108.
11. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's role in cancer suppression and promotion. Science 331(6024): 1565-1570.
12. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235-271.
13. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2): 137-148.
14. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11): 991-998.
15. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795): 1960-1964.
16. Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, et al. (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27(35): 5944-5951.
17. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, et al. (2006) Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung cancer. Br J Cancer 94(2): 275-280.
18. Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, et al. (2008) Predominant infiltration of macrophages and CD8(+) T cells in cancer nests is a statistically relevant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113(6): 1387-1395.
19. Ashida A, Boku N, Aoyagi K, Sato H, Tsubosa Y, et al. (2006) Expression profiling of esophageal squamous cell cancer patients treated with definitive chemoradiotherapy: clinical implications. Int J Oncol 28(6): 1345-1352.
20. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, et al. (2003) CD4+ and CD8+ T cells cooperate to improve prognosis of the patients with esophageal squamous cell cancer. Cancer Res 63(7): 1555-1559.
21. Hamanishi J, Mandai M, Abiko K, Matsumura N, Baba T, et al. (2011) The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol 141(3): 338-347.
22. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3): 203-213.
23. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, et al. (2001) Proliferative activity of intratumoral CD8(+) T lymphocytes as a prognostic factor in human renal cell cancer: clinicopathological demonstration of antitumor immunity. Cancer Res 61(13): 5132-5136.
24. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, et al. (2004) CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28(1): e26-31.
25. Mahmoud SM, Paish EC, Powe DG, Macmi llan RD, Grainge MJ, et al. (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15): 1949-1955.
26. Liu F, Lang R, Zhao J, Zhang X, Pringle GA, et al. (2011) CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 130(2): 645-655.
27. Baker K, Lachapelle J, Zlobec I, Bismas TA, Terracciano L, et al. (2011) Prognostic significance of CD8 (+) T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 58(7): 1107-1116.
28. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, et al. (2012) CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basallike breast cancer. Breast Cancer Res 14(2): R48.
29. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) Reporting recommendations for tumor marker prognostic studies (RE-MARK). Breast Cancer Res Treat 100(2): 229-235.
30. Anz D, Eiber S, Scholz C, Endres S, Kirchner T, et al. (2011) In breast cancer, a high ratio of tumour-infiltrating intraepithelial CD8+ to FOXP3+ cells is characteristic for the medullary subtype. Histopathology 59(5): 965-974.
31. Alexe G, Dalgin GS, Scanfeld D, Tamayo P, Mesirov JP, et al. (2007) High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res 67(22): 10669-10676.
32. Lee AHS, Gillett CE, Ryder K, Fentiman IS, Miles DW, et al. (2006) Different patterns of inflammation and prognosis in invasive cancer of the breast. Histopathology 48(6): 692-701.
33. DeNardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9(4): 212.
34. Ménétrier-Caux C, Gobert M, Caux C (2009) Different in tumor regulatory Tcell localization and activation status impact patient outcome. Cancer Res 69(20): 7895-7898.
35. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-leon S, et al. (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69(5): 2000-2009.
36. Calabrò A, Beissbarth T, Kuner R, Stojanov M, Benner A, et al. (2009) Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 116(1): 69-77.
37. Oh E, Choi Y, Park T, Lee S, Nam SJ, et al. (2012) A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity. Breast Cancer Res Treat 132(2): 499-509.
38. Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, et al. (2007) CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 13(9): 2714-2721.